Zydus is one of the oldest players in the Indian formulations market for several years. There has been a continuous thrust on improving market presence and market share. It has expanded its portfolio by entering newer therapeutic areas organically or through acquisitions, aggressively launching new products with the first mover advantage in several products, gradually shifting its focus from acute segments to fast growing and sustainable chronic segments and enhancing market penetration through field force expansion. These strategic initiatives have helped Zydus become one of the dominant players in the Indian formulations market with the leadership position in several therapeutic categories.
The group has built strong positions in key segments of Cardiovasculars, Gastrointestinals, Women’s Healthcare and holds leading positions in other therapeutic segments such as Respiratory, Pain Management and Antiinfectives.
Recently, the group has set up a new speciality division, Zydus Discovery dedicated to marketing the innovative therapies and molecules developed by the company. Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia indigenously developed by Zydus is marketed by Zydus Discovery.
Consumer Products Business - Zydus Wellness Ltd.